论文部分内容阅读
血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)是一种具有较高特异性的血管生成因子,VEGF通过与血管内皮细胞生长因子受体家族(vascular endothelial growth factor receptor family,VEGFRs)相互作用,促进血管内皮细胞和淋巴内皮细胞的增殖和分化、调节血管通透性,从而在生理性和病理性血管形成过程中发挥调节作用。近年来,以VEGF及其受体为靶点的抗肿瘤治疗受到越来越多的关注,妇产科常见三大恶性肿瘤:卵巢癌、子宫内膜癌及宫颈癌的发展与VEGF、VEGFR2的表达也存在相关性,本文重点介绍以VEGFR2为靶点的抗肿瘤治疗在卵巢癌、子宫内膜癌及宫颈癌中的研究进展。
Vascular endothelial growth factor (VEGF) is a kind of angiogenic factor with high specificity. VEGF interacts with vascular endothelial growth factor receptor family (VEGFRs) Promote the proliferation and differentiation of vascular endothelial cells and lymphatic endothelial cells, regulate the permeability of blood vessels, and thus play a regulatory role in the process of physiological and pathological blood vessel formation. In recent years, VEGF and its receptors as the target of anti-tumor treatment by more and more attention, obstetrics and gynecology common three malignant tumors: ovarian cancer, endometrial cancer and cervical cancer and VEGF, VEGFR2 Expression is also related, this article focuses on the VEGFR2 as a target anti-cancer treatment in ovarian cancer, endometrial cancer and cervical cancer research progress.